Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Stifel 2025 Healthcare Conference November 11, 2025 9:20 AM EST Stephens Investment Conference November 18, 2025 8:00 AM CST Jefferies Global Healthcare Conference November 20, 2025 12:30 PM GMT […]
Chief Digital & Analytics Officer Katya Andresen to lead Excellence & Transformation Initiatives Global health company The Cigna Group (NYSE: CI) today announced that Dr. Amy Flaster has been named Chief Medical Officer of The Cigna Group, effective November 1. Dr. Flaster, who joined the company last year as Chief Medical Officer of Cigna Healthcare,
CIBC (TSX: CM) (NYSE: CM) – CIBC Asset Management Inc. (CAM) today announced the launch of three new CIBC Exchange Traded Funds (ETFs) – each fund is managed by CIBC's experienced portfolio management team. TSX Ticker ETF Name Target Asset Mix Management Fee*CCON CIBC Conservative ETF Portfolio – 60% fixed income and 0.15% ETF Class
(NASDAQ:IRD), – Financing led by Perceptive Advisors and Balyasny Asset Management – – Proceeds targeted to fund rapid development of ophthalmic gene therapy clinical programs – RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”) a clinical-stage biopharmaceutical company developing gene therapies for the
(NASDAQ:ADV), Strong Revenues and Adjusted EBITDA growth in Experiential Services partially offsetting softness in Branded Services Generated $98 million in adjusted unlevered free cash flow and ended the quarter with strong cash position of $201 million Rapidly responded to robust demand in high-volume labor businesses generating strong incremental margin Reaffirm Revenue and modestly lower Adjusted
(NASDAQ:IRD), Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5 First participant enrolled in run-in period for planned adaptive Phase 3 trial Company intends to apply for the FDA's new Rare Disease Evidence Principles (RDEP) review process OPGx-LCA5 has the potential to be the
(CNSX:MAXX),(CNSX:MAXX.CN),(Pinksheets:MAXXF),(PinkSheets:MAXXF),(Boerse Frankfurt – Freiverkehr:89N.F),(Boerse Frankfurt – Freiverkehr:89N), Saskatchewan Energy Leader Tom Kishchuk, Executive Director of the Global Institute for Energy, Minerals and Society, Joins MAX Power Board as Canada's First-Ever Natural Hydrogen Drill Program Gets Set To Begin MAX Power Saskatchewan Natural Hydrogen Documentary Videohttps://www.maxpowermining.com/NaturalHydrogen-NewEra/ SASKATOON, Saskatchewan, Nov. 06, 2025 (GLOBE NEWSWIRE) — MAX Power
(NasdaqGM:RAPP), Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline results expected in the first half of 2027 Strong balance sheet, bolstered by approximately $269.4 million in net proceeds from recent public
(NYSE Arca:BLOK),(CBOE:BITY),(CBOE:BAGY),(CBOE:ETTY),(CBOE:EHY),(NYSE Arca:SOLM), CHICAGO, Nov. 06, 2025 (GLOBE NEWSWIRE) — Amplify ETFs, a leading provider of breakthrough ETF solutions, has been named Best Crypto-Linked ETF Issuer ($100 million-$1 billion) by ETF Express, recognizing the firm's pioneering role and continued contributions in the evolving digital assets ETF landscape. As of Nov. 4, 2025, Amplify has six
(NasdaqGM:MAZE), SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced seven presentations at the American Society of Nephrology's (ASN) Kidney Week, being held November 6-9 in Houston, Texas. During the meetings,